Clin2
NCT05430009Possibly a fitRecruiting

Radiation to liver plus immunotherapy for metastatic lung cancer

Liver MetastasesNon-small Cell Lung Cancer

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re an adult (18 or older)
  • You have non-small cell lung cancer confirmed by biopsy or body-fluid test, and it has spread to the liver
  • Your cancer can be measured on scans (doctors need measurable tumors)
  • You’re well enough to do daily activities (ECOG 0 to 2)
  • Your liver, kidney, and blood tests meet the study’s organ-function rules
  • You must be able to take immunotherapy (your oncologist agrees) and sign consent

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05657873Recruiting· Phase 2
Targeted radiation for metastatic lung cancer with liver spread

This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).

Miami, Florida
NCT06794086Recruiting· Phase 3
SBRT and immunotherapy for colorectal cancer liver metastases

This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).

Guangzhou, Guangdong
NCT07225036Recruiting
Low-dose liver radiation to boost immunotherapy

This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.

Cincinnati, Ohio
NCT06434740Not yet recruiting· Phase 2
SBRT and puterizumab for lung metastases

This trial tests a combination of targeted radiation (SBRT) and an immunotherapy drug (puterizumab) for people whose non-small cell lung cancer has spread to the lungs after previous immunotherapy. The goal is to see if the combination can help control the cancer.

NCT06686771Recruiting· Phase 3
Radiation for limited growth in advanced lung cancer on immunotherapy

This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.

Phoenix, Arizona
NCT02185443Recruiting· Phase 2
SBRT radiation for liver metastases that can’t be surgically removed

This trial studies stereotactic body radiation therapy (high-precision radiation given in a few sessions) for liver metastases when surgery isn’t possible. It may help shrink or control tumors in the liver and delay progression in people whose cancer has not spread outside the liver (or only to areas treated with a curative plan).

São Paulo, São Paulo

Hear when a new Liver Metastases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.